A Survey of the Criteria Used for the Selection of Alternative Comparator Products by Participating Regulators and Organizations of the International Pharmaceutical Regulators Programme

• Egile Nagusiak: Andrew Tam (Egilea), Alfredo Garcia-Arieta (Egilea), Ivana Abalos (Egilea), Eduardo Agostinho Freitas Fernandes (Egilea), Gustavo Mendes Lima Santos (Egilea), Zulema Rodriguez Martinez (Egilea), Milly Divinsky (Egilea), Rami Kariv (Egilea), Henrike Potthast (Egilea), April C. Braddy (Egilea), Clare Rodrigues (Egilea), Erwin Guzman Aurela (Egilea), Liliana Carolina Arevalo Gonzalez (Egilea), Diego Gutierres Triana (Egilea), Ben Jones (Egilea), Choongyul Ahn (Egilea), Hyuna Kim (Egilea), So Hee Kim (Egilea), Ryosuke Kuribayashi (Egilea), Aya Myoenzono (Egilea), Kohei Shimojo (Egilea), Joy van Oudtshoorn (Egilea), Cornelia Bigler (Egilea), Ricarda Meincke (Egilea), Matthias S. Roost (Egilea), Chantal Walther (Egilea), Li-feng Hsu (Egilea), Christopher Crane (Egilea), Tony Jarman (Egilea)
• Formatua: Liburua
• Argitaratua: Frontiers Media S.A., 2022-10-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

The safety and efficacy of a generic product are partly based on demonstrating bioequivalence to the innovator product; however, when the innovator product is no longer available as a comparator product, a survey conducted within the Bioequivalence Working Group for Generics (BEWGG) of the Internati...